Gamma Medica Notes Achievements of LumaGEM MBI in Early Breast Cancer Detection

Gamma Medica Notes Achievements of LumaGEM MBI in Early Breast Cancer Detection
Gamma Medica presented clinical evidence confirming that adding its LumaGEM Molecular Breast Imaging system to mammography as a secondary screening method is more than twice as effective as mammogram plus ultrasound in detecting breast cancer in women with dense breast tissue. The presentation was made at this year’s Radiological Society of North America 102nd annual meeting (RSNA 2016) Nov. 27 to Dec 2 in Chicago. The clinical results presented at the meeting were published in the American Journal of Roentgenology under the title “Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue.” This study featured LumaGEM to prove the benefits of molecular breast imaging (MBI) versus mammograms for dense breast tissue in women, which includes about half of the women in the U.S. Breast cancer diagnosis is not perfect. Dense breast tissue and cancer both appear white on mammograms, sometimes making it difficult to distinguish between the two. As a result, some women with dense breast tissue receive a negative mammogram result when they do have breast cancer. LumaGEM's MBI technology is an imaging modality that improves early and accurate breast cancer detection for these women, with recent studies confirming that MBI highlights metabolic activity in breast tumors not visible on mammograms due to tissue dens
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.